Journal
LEUKEMIA & LYMPHOMA
Volume 57, Issue 1, Pages 92-98Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2015.1041388
Keywords
L-kynurenine; immunological tolerance; indoleamine 2; 3-dioxygenase; prognostic factor; L-tryptophan catabolism; acute myeloid leukemia (AML)
Categories
Ask authors/readers for more resources
The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze the breakdown of the L-tryptophan along the L-kynurenine pathway. Because blasts from patients with acute myeloid leukemia (AML) express IDO, the goal of this study was to investigate the role of L-kynurenine as a prognostic marker for AML. We enrolled 48 AML patients. L-kynurenine concentrations were measured by high-performance liquid chromatography. The median serum L-kynurenine level was 1.67 M. There was no significant difference in the complete remission rate between patients with L-kynurenine < 2.4 (77%) and 2.4 M (75%). However, 3-year overall survival (OS) rates were significantly better in patients with low L-kynurenine levels (76%) than in those with high L-kynurenine levels (11%) (p < 0.0001). Furthermore, in intermediate-risk cytogenetics patients, only L-kynurenine was significantly associated with OS (p < 0.005). Multivariate analyses revealed that L-kynurenine and high leukocyte count were independent prognostic factors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available